Novo Nordisk A/S (NYSE:NVO) Shares Sold by Central Bank & Trust Co.

Central Bank & Trust Co. reduced its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 23.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,755 shares of the company's stock after selling 6,332 shares during the period. Central Bank & Trust Co.'s holdings in Novo Nordisk A/S were worth $1,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after purchasing an additional 1,165,955 shares during the period. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after buying an additional 5,556,460 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares in the last quarter. Folketrygdfondet grew its stake in Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company's stock valued at $765,917,000 after acquiring an additional 40,313 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in Novo Nordisk A/S by 1.5% in the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company's stock worth $715,084,000 after acquiring an additional 123,681 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the subject of a number of research analyst reports. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Friday. Finally, Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Price Performance

NVO traded up $0.82 during trading on Monday, reaching $75.45. The company's stock had a trading volume of 10,865,984 shares, compared to its average volume of 6,921,002. The company has a market cap of $338.59 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 0.90 and a beta of 0.66. The firm has a fifty day simple moving average of $65.87 and a two-hundred day simple moving average of $80.38. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion during the quarter. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.